A syngeneic glioma model of wild-type and IDH1-mutated cancers demonstrated no change in survival in RAG2 knockout mice, indicating that suppression of anti-tumor response mediates the competitive advantage of R-2-HG production in vivo. The gene discussed is IDH1; the disease is neoplasm.